Journal
HUMAN GENE THERAPY CLINICAL DEVELOPMENT
Volume 24, Issue 3, Pages 134-142Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/humc.2013.144
Keywords
-
Categories
Funding
- National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St. Thomas' NHS Foundation Trust
- NIHR Biomedical Research Centre based at Guy's and St. Thomas' NHS Foundation Trust and King's College London
- Experimental Cancer Medicine Centre at King's College London
- Jon Moulton Charitable Foundation
- Academy of Medical Sciences (AMS) [AMS-SGCL6-Papa] Funding Source: researchfish
- National Institute for Health Research [CL-2011-17-007] Funding Source: researchfish
- Prostate Cancer UK [PA12-06] Funding Source: researchfish
Ask authors/readers for more resources
Despite several advances, 5-year survival in patients with head and neck squamous cell carcinoma (HNSCC) remains unchanged at only 50%. The commonest cause of death is locally advanced/recurrent disease. Consequently, there is an unmet need for new approaches to improve local control in HNSCC. T4 immunotherapy is an autologous cell therapy in which peripheral blood T-cells are genetically engineered using a retroviral vector to coexpress two chimeric receptors: (i) T1E28z is a chimeric antigen receptor that engages multiple ErbB dimers that are commonly upregulated in HNSCC; (ii) 4 alpha beta is a chimeric cytokine receptor that converts the weak mitogenic stimulus provided by interleukin (IL)-4 into a strong and selective growth signal, allowing preferential expansion and enrichment of T4(+) T-cells ex vivo. T4 immunotherapy exerts antitumor activity against HNSCC cell lines and tumors in vivo, without significant toxicity. Human T4(+) T-cells also engage mouse ErbB receptors, permitting safety testing in SCID Beige mice. Severe toxicity caused by cytokine release syndrome ensues when human T4(+) T-cells are administered at high doses to mice, particularly with advanced tumor burdens. However, such toxicity is not required for efficacy and is never seen if T-cells are administered by the intratumoral route. To exploit this, we have designed a first-in-man clinical trial in which T4(+) T-cells are administered to patients with locally advanced/recurrent HNSCC. Cells will be administered at a single sitting to multiple sites around the viable tumor circumference. A 3 + 3 dose escalation design will be used, starting at 10(7) cells (cohort 1), escalating to 10(9) cells (cohort 5). If maximum tolerated dose remains undefined, cohorts 6/7 will receive either low- or high-dose cyclophosphamide before 10(9) T4(+) T-cells. A panel of routine/in-house assays and imaging techniques will be used to monitor safety, efficacy, perturbation of endogenous antitumor immunity, immunogenicity, and T-cell trafficking.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available